A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity

AIDS

Volumn 28, Issue 16, 2014, Pages 2355-2364

  Giagulli, Cinzia ^a   Caccuri, Francesca ^a   Cignarella, Francesca ^a   Lougaris, Vassilios ^a   Martorelli, Debora ^b   Bugatti, Antonella ^a   Rusnati, Marco ^a   Dolcetti, Riccardo ^b   Vitali, Massimiliano ^a   Plebani, Alessandro ^a   Fiorentini, Simona ^a   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Adhesion; CXCR1; CXCR1 300 142; Glu Leu Arg motif; HIV 1 matrix protein p17; IL 8; Migration

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CXCR1; GLUTAMIC ACID; INTERLEUKIN 8; LEUCINE; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P17; VASCULAR CELL ADHESION MOLECULE 1; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; PROTEIN BINDING;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENT CELL; JURKAT CELL LINE; MONOCYTE; MUTAGENESIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN MOTIF; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE PLASMON RESONANCE; CELL MOTION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

CELL MOVEMENT; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HAPLOTYPES; HIV ANTIGENS; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-8; JURKAT CELLS; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-8A; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES;

EID: 84916603257     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000423     Document Type: Article

References (42)

1. Vasilescu A, Terashima Y, Enomoto M, Heath S, Poonpiriya V, Gatanaga H, et al. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc Natl Acad Sci USA 2007;104:3354-3359.
2. Matsumoto T, Miike T, Nelson RP, Trudeau WL, Lockey RF, Yodoi J. Elevated serum levels of IL-8 in patients with HIV infection. Clin Exp Immunol 1993;93:149-151.
3. Meddows-Taylor S, Martin DJ, Tiemessen CT. Dysregulated production of interleukin-8 in individuals infected with human immunodeficiency virus type 1 and Mycobacterium tuberculosis. Infect Immun 1999;67:1251-1260.
4. Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, Strieter RM, et al. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol 2001;75:8195-8202.
5. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA. Single amino acid changesin the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 1994;68:5311-5320.
6. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci USA 2003;100:10592-10597.
7. Fiorentini S, Riboldi E, Facchetti F, Avolio M, Fabbri M, Tosti G, et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci USA 2008;105:3867-3872.
8. Budka H. Human immunodeficiency virus (HIV) envelope and core proteins in CNS tissues of patients with the acquired immune deficiency syndrome (AIDS). Acta Neuropathol 1990;79:611-619.
9. Caccuri F, Giagulli C, Bugatti A, Benetti A, Alessandri G, Ribatti D, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci USA 2012;109:14580-14585.
10. Wiley EL, Nightingale SD. Opportunistic events and p17 expressioninthe bone marrowofhuman immunodeficiency virusinfected patients. J Infect Dis 1994;169:617-620.
11. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 2005;102:14807-14812.
12. Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol Ther 2010;128:433-444.
13. De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci USA 2002;99:9972-9977.
14. Giagulli C, Magiera AK, Bugatti A, Caccuri F, Marsico S, Rusnati M, et al. HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood 2012;119:2274-2283.
15. Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Régulier EG, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001;7:528-541.
16. Giagulli C, Marsico S, Magiera AK, Bruno R, Caccuri F, Barone I, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 2011;6:17831.
17. Rich RL, Errey J, Marshall F, Myszka DG. Biacore analysis with stabilized G-protein-coupled receptors. Anal Biochem 2011;409:267-272.
18. Alves ID, Park CK, Hruby VJ. Plasmon resonance methods in GPCR signaling and other membrane events. Curr Protein Pept Sci 2005;6:293-312.
19. Poiesi C, De Francesco MA, Baronio M, Manca N. HIV-1 p17 binds heparan sulfate proteoglycans to activated CD4 (+) T cells. Virus Res 2008;132:25-32.
20. Blumer KJ, Johnson GL. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci 1994;19:236-240.
21. Jones SA, Moser B, Thelen M. A comparison of postreceptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated activation of p42/p44 MAP-kinase (ERK-2). FEBS Lett 2008;364:211-214.
22. Rajagopalan L, Rajarathnam K. Structural basis of chemokine receptor function: a model for binding affinity and ligand selectivity. Biosci Rep 2006;26:325-339.
23. Hébert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 1991;266:18989-18994.
24. Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem 1994;269:16075-16081.
25. Rajagopalan L, Rajarathnam K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J Biol Chem 2004;279:30000-30008.
26. Bissantz C. Conformational changes of G protein-coupled receptors during their activation by agonist binding. J Recept Signal Transduct Res 2003;23:123-153.
27. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-proteincoupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 2004;103:21-80.
28. Wu L, Ruffing N, Shi X, Newman W, Soler D, Mackay CR, et al. Discrete steps in binding and signaling of interleukin-8 with its receptor. J Biol Chem 1996;271:31202-31209.
29. Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, et al. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH. Biopolymers 2004;76:334-343.
30. Fiorentini S, Marsico S, Becker PD, Iaria ML, Bruno R, Guzmán CA, et al. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine 2008;26:4758-4765.
31. Shoemaker BA, Portman JJ, Wolynes PG. Speeding molecular recognition by using the folding funnel: the fly-casting mechanism. Proc Natl Acad Sci USA 2000;97:8868-8873.
32. Ali H, Richardson RM, Haribabu B, Snyderman R. Chemoattractant receptor cross-desensitization. J Biol Chem 1999;274:6027-6030.
33. Rodríguez-Frade JM, Mellado M, Martínez AC. Chemokine receptor dimerization: two are better than one. Trends Immunol 2001;22:612-617.
34. Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 2004;16:175-186.
35. Mellado M, Rodríguez-Frade JM, Vila-Coro AJ, Fernández S, Martín de Ana A, Jones DR, et al. Chemokine receptor homo or heterodimerization activates distinct signaling pathways. EMBO J 2001;20:2497-2507.
36. Zhu XG, McPhie P, Cheng SY. Differential sensitivity of thyroid hormone receptor isoform homodimers and mutant heterodimers to hormone-induced dissociation from deoxyribonucleic acid: its role in dominant negative action. Endocrinology 1997;138:1456-1463.
37. Springael JY, Urizar E, Parmentier M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 2005;16:611-623.
38. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 1997;272:30603-30606.
39. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995;182:219-231.
40. Bugatti A, Giagulli C, Urbinati C, Caccuri F, Chiodelli P, Oreste P, et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J Biol Chem 2013;288:1150-1161.
41. Haffar O, Dubrovsky L, Lowe R, Berro R, Kashanchi F, Godden J, et al. Oxadiazols: a new class of rationally designed antihuman immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein. J Virol 2005;79:13028-13036.
42. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-497.